News Daiichi Sankyo’s pexidartinib is first FDA-approved drug for... /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;
News Novartis weathers Entresto slump with return to growth Novartis saw sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by generic competition to Entresto.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
